COLUMN13Product CodeM1220M5250M6060M1210M5220BM5250BM6050EM1180CM6050CMaruho actively promotes LCM by utilizing its “nurturing capabilities,” a strength Maruho has maintained since its founding. In February 2021, we added indications of scalp eczema and dermatitis to Comclo Shampoo. The expansion of the indication for this shampoo, which had been limited to psoriasis, has enabled us to greatly contribute to relieving patients from their scalp itchiness and dandruff, troubles that undermine their QOL significantly. Zebiax Oily Cream, an anti-microbial topical agent launched in June 2021, is an additional dosage form of the existing Zebiax Lotion. It can be indicated for the treatment of contagious impetigo and acne. For the treatment of impetigo, it is highly regarded by medical professionals as a mild, highly adhesive oily cream expected to protect patients’ skin. As topical agents are required to have dosage forms appropriate for the patients’ skin conditions, we believe that we can contribute to better health for patients suffering from skin diseases by adding dosage forms and expanding their choice. Maruho is also committed to promoting digital research RosaceaPruritus with atopic dermatitis (adults)* Phase Ⅲ studies in progress for pediatricPrimary axillary hyperhidrosisIngrown nailsRecurrent herpes simplexPruritus with prurigo nodularisAcne vulgarisPrurigo nodularisAcne vulgarisTarget Indication*1 LCM (Life Cycle Management): An approach to maximizing product value by expanding indications for, adding dosage forms to, and modifying dosage and administration of, existing products*2 DR (Drug Repositioning): A process of finding the therapeutic efficacy of an existing drug available for other diseases(From front left) Research Dept. Hiromi Baba (Board member of LINC), Misuzu Takahashi(From rear left) Kotaro Iwasaki, Ryosuke Yoshimune, Tomoya MaedaDosage FormDevelopment Phaseand development using artificial inteligence (AI) technology, with the aim of accelerating DR*2. We will continue to make efforts to create high-quality products and enhance our development pipeline for the purpose of contributing to the improved QOL of patients seeking better health.In August 2021, it was decided to use Fugaku, one of the world’s most powerful supercomputers, for our formulation design simulation. In line with activities at the Life Intelligence Consortium (LINC), the largest-scale consortium in the field of life sciences in Japan established mainly for the development of AI for drug discovery, we will make use of the knowledge and technologies obtained to dramatically accelerate and improve the efficiency of our R&D activities, and thereby create innovative products.TopicalFiled for approvalInjectionFiled for approvalTopicalFiled for approvalTopicalOralInjectionTopicalTopicalTopicalAdditional indicationPhase IIIPhase IIIAdditional indicationPhase IIIAdditional indicationPhase IIIAdditional dosage formPhase IIAdditional indicationPhase IINotesResearch and Development(As of September 30)Maximizing product value by LCM*1 initiativesDevelopment Pipeline （Includes late-stage development products after Phase II in Japan）
元のページ ../index.html#15